Jan 21, 2020 - Chinese drugmaker BeiGene would compete directly with Merck's cancer superdrug.
Jan 21, 2020 - The blockbuster drug is already approved for three other types of tumors.
Jan 20, 2020 - Merck & Co. (MRK) stock may be a good choice for value-oriented investors right now from multiple angles.
Jan 17, 2020 - J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
Jan 17, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Jan 16, 2020 - Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
Jan 16, 2020 - The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
Jan 15, 2020 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jan 14, 2020 - AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee
Jan 13, 2020 - Merck & Co., Inc. (NYSE:MRK) Annual J.P. Morgan Healthcare Conference January 13, 2020 7:30 p.m. ET Company Participants Ken Frazier - Chairman and CEO Roger Perlmutter - President of Merck Resear